Premium
Dystrophin Abnormality in Progressive Muscular Dystrophy ‐A Review Article‐
Author(s) -
Arahata Kiichi
Publication year - 1991
Publication title -
pediatrics international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.49
H-Index - 63
eISSN - 1442-200X
pISSN - 1328-8067
DOI - 10.1111/j.1442-200x.1991.tb01546.x
Subject(s) - dystrophin , medicine , sarcolemma , muscular dystrophy , itga7 , duchenne muscular dystrophy , abnormality , skeletal muscle , bioinformatics , pathology , biology , psychiatry
Duchenne muscular dystrophy (DMD) is a fatal X‐linked recessive disorder of muscle in children, with an incidence of approximately 1 in 3,300 male births. In about a third of affected boys, the disease is due to a new mutation, and most patients die in their early 20s. Over the last few years, the genetic, biochemical and histopathological basis of DMD has been elucidated greatly. In particular, the discovery of “dystrophin,” the protein product of the DMD gene is truly an epoch‐making success in the history of muscular dystrophy research. Dystrophin is now thought to be a cytoskeletal protein underlying the plasma membrane (known in muscle as the sarcolemma) of normal muscle fiber, and is undetectable or greatly reduced in DMD. In this review article, dystrophin in normal skeletal muscle and various neuromuscular diseases including DMD/BMD (Becker muscular dystrophy), and its carrier is discussed.